RU2009116273A - Вакцина ipv-dpt - Google Patents
Вакцина ipv-dpt Download PDFInfo
- Publication number
- RU2009116273A RU2009116273A RU2009116273/15A RU2009116273A RU2009116273A RU 2009116273 A RU2009116273 A RU 2009116273A RU 2009116273/15 A RU2009116273/15 A RU 2009116273/15A RU 2009116273 A RU2009116273 A RU 2009116273A RU 2009116273 A RU2009116273 A RU 2009116273A
- Authority
- RU
- Russia
- Prior art keywords
- microcarrier
- purification
- poliomyelitis virus
- virus
- stage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32361—Methods of inactivation or attenuation
- C12N2770/32363—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1. Способ получения комбинированной вакцины, содержащей: ! (A) инактивированный штамм Сэбина вируса полиомиелита, ! (B) защитный антиген Bordetella pertussis, ! (C) анатоксин дифтерии, и ! (D) анатоксин столбняка, ! способ включает (a) стадию культивирования в присутствии от примерно 4 г/л до примерно 6 г/л микроносителя клеток Vero для инокуляции штаммом Сэбина вируса полиомиелита. ! 2. Способ по п.1, дополнительно включающий: ! (b) стадию инфицирования клеток Vero штаммом Сэбина вируса полиомиелита; ! (c) стадию, представляющую возможность вирусу полиомиелита пролиферировать; ! (d) стадию восстановления вирусной жидкости, содержащей вирус полиомиелита; и ! (e) стадию инактивации вируса полиомиелита. ! 3. Способ по п.1, в котором микроноситель имеет концентрацию примерно 5 г/л. ! 4. Способ по п.1, в котором микроносителем является декстрановый микроноситель. ! 5. Способ по п.1, в котором стадию культивирования клеток Vero (стадия (a)) проводят в объеме по меньшей мере примерно 3 л. ! 6. Способ по п.1, в котором стадию культивирования клеток Vero (стадия (a)) проводят в объеме по меньшей мере примерно 30 л. ! 7. Способ по п.2, дополнительно включающий ! (d-2) стадию очистки вирусной жидкости. ! 8. Способ по п.7, в котором стадия очистки (стадия (d-2)) включает: ! (i) преобразование вирусной жидкости, восстановленной на стадии (d), в осадок путем ультрацентрифугирования, ! (ii) обработку ультразвуком ресуспензии осадка; и ! (iii) очистку колоночной хроматографией. !9. Способ по п.8, в котором очистку колоночной хроматографией (iii) проводят только один раз. ! 10. Вакцина, полученная способом по п.1.
Claims (10)
1. Способ получения комбинированной вакцины, содержащей:
(A) инактивированный штамм Сэбина вируса полиомиелита,
(B) защитный антиген Bordetella pertussis,
(C) анатоксин дифтерии, и
(D) анатоксин столбняка,
способ включает (a) стадию культивирования в присутствии от примерно 4 г/л до примерно 6 г/л микроносителя клеток Vero для инокуляции штаммом Сэбина вируса полиомиелита.
2. Способ по п.1, дополнительно включающий:
(b) стадию инфицирования клеток Vero штаммом Сэбина вируса полиомиелита;
(c) стадию, представляющую возможность вирусу полиомиелита пролиферировать;
(d) стадию восстановления вирусной жидкости, содержащей вирус полиомиелита; и
(e) стадию инактивации вируса полиомиелита.
3. Способ по п.1, в котором микроноситель имеет концентрацию примерно 5 г/л.
4. Способ по п.1, в котором микроносителем является декстрановый микроноситель.
5. Способ по п.1, в котором стадию культивирования клеток Vero (стадия (a)) проводят в объеме по меньшей мере примерно 3 л.
6. Способ по п.1, в котором стадию культивирования клеток Vero (стадия (a)) проводят в объеме по меньшей мере примерно 30 л.
7. Способ по п.2, дополнительно включающий
(d-2) стадию очистки вирусной жидкости.
8. Способ по п.7, в котором стадия очистки (стадия (d-2)) включает:
(i) преобразование вирусной жидкости, восстановленной на стадии (d), в осадок путем ультрацентрифугирования,
(ii) обработку ультразвуком ресуспензии осадка; и
(iii) очистку колоночной хроматографией.
9. Способ по п.8, в котором очистку колоночной хроматографией (iii) проводят только один раз.
10. Вакцина, полученная способом по п.1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006-267439 | 2006-09-29 | ||
| JP2006267439 | 2006-09-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009116273A true RU2009116273A (ru) | 2010-11-10 |
| RU2447898C2 RU2447898C2 (ru) | 2012-04-20 |
Family
ID=39282813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009116273/15A RU2447898C2 (ru) | 2006-09-29 | 2007-09-28 | Вакцина ipv-dpt |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8753646B2 (ru) |
| EP (1) | EP2075005B1 (ru) |
| JP (2) | JP4874339B2 (ru) |
| KR (2) | KR20150080643A (ru) |
| CN (3) | CN105126095A (ru) |
| AU (1) | AU2007305595C1 (ru) |
| BR (1) | BRPI0717145A2 (ru) |
| CA (1) | CA2664799C (ru) |
| ES (1) | ES2560452T3 (ru) |
| HK (1) | HK1129836A1 (ru) |
| MX (1) | MX2009002909A (ru) |
| NZ (1) | NZ574776A (ru) |
| RU (1) | RU2447898C2 (ru) |
| WO (1) | WO2008044611A1 (ru) |
| ZA (1) | ZA200902155B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| US10092640B2 (en) | 2011-01-05 | 2018-10-09 | Bharat Biotech International Limited | Combination heptavalent vaccine |
| CN102178949A (zh) * | 2011-05-13 | 2011-09-14 | 中国医学科学院医学生物学研究所 | 吸附无细胞百白破-Sabin株脊髓灰质炎联合疫苗及其制备 |
| US10787646B2 (en) | 2015-10-02 | 2020-09-29 | Baylor College Of Medicine | Cultivation of human noroviruses |
| CA3141460A1 (en) | 2019-05-20 | 2020-11-26 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4525349A (en) * | 1981-12-29 | 1985-06-25 | Societe Anonyme Dite: Institut Merueux | Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine |
| US6696065B1 (en) * | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
| TR199802783T2 (xx) | 1996-07-02 | 1999-03-22 | Connaught Laboratories Limited | �ok de�erli DTP polyo a��lar. |
| BRPI0419023A (pt) | 2004-08-27 | 2007-12-11 | Panacea Biotec Ltd | vacina contra poliomielite inativada e derivada do genero sabin de vìrus da polio |
| CN1297313C (zh) * | 2004-09-16 | 2007-01-31 | 中国医学科学院医学生物学研究所 | 减毒株脊髓灰质炎灭活疫苗后处理方法 |
| WO2008028957A2 (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
-
2007
- 2007-09-28 WO PCT/JP2007/069509 patent/WO2008044611A1/ja active Application Filing
- 2007-09-28 CN CN201510553022.5A patent/CN105126095A/zh active Pending
- 2007-09-28 CA CA2664799A patent/CA2664799C/en not_active Expired - Fee Related
- 2007-09-28 US US12/311,365 patent/US8753646B2/en not_active Expired - Fee Related
- 2007-09-28 BR BRPI0717145-5A patent/BRPI0717145A2/pt not_active IP Right Cessation
- 2007-09-28 MX MX2009002909A patent/MX2009002909A/es active IP Right Grant
- 2007-09-28 ZA ZA200902155A patent/ZA200902155B/xx unknown
- 2007-09-28 CN CN2013100910144A patent/CN103223163A/zh active Pending
- 2007-09-28 KR KR1020157016625A patent/KR20150080643A/ko not_active Application Discontinuation
- 2007-09-28 AU AU2007305595A patent/AU2007305595C1/en not_active Ceased
- 2007-09-28 EP EP07829247.1A patent/EP2075005B1/en active Active
- 2007-09-28 RU RU2009116273/15A patent/RU2447898C2/ru active
- 2007-09-28 CN CNA2007800362477A patent/CN101522209A/zh active Pending
- 2007-09-28 KR KR1020097007730A patent/KR101617464B1/ko active IP Right Grant
- 2007-09-28 JP JP2008538693A patent/JP4874339B2/ja active Active
- 2007-09-28 NZ NZ574776A patent/NZ574776A/en not_active IP Right Cessation
- 2007-09-28 ES ES07829247.1T patent/ES2560452T3/es active Active
-
2009
- 2009-08-06 HK HK09107222.6A patent/HK1129836A1/zh not_active IP Right Cessation
-
2011
- 2011-06-06 JP JP2011126139A patent/JP2011201913A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007305595A1 (en) | 2008-04-17 |
| MX2009002909A (es) | 2009-03-31 |
| JP4874339B2 (ja) | 2012-02-15 |
| EP2075005B1 (en) | 2015-12-02 |
| CN103223163A (zh) | 2013-07-31 |
| KR20090057442A (ko) | 2009-06-05 |
| US8753646B2 (en) | 2014-06-17 |
| ZA200902155B (en) | 2010-06-30 |
| NZ574776A (en) | 2012-03-30 |
| KR101617464B1 (ko) | 2016-05-02 |
| CN101522209A (zh) | 2009-09-02 |
| CN105126095A (zh) | 2015-12-09 |
| KR20150080643A (ko) | 2015-07-09 |
| RU2447898C2 (ru) | 2012-04-20 |
| JPWO2008044611A1 (ja) | 2010-02-12 |
| BRPI0717145A2 (pt) | 2013-11-12 |
| WO2008044611A1 (en) | 2008-04-17 |
| ES2560452T3 (es) | 2016-02-19 |
| US20100021497A1 (en) | 2010-01-28 |
| HK1129836A1 (zh) | 2009-12-11 |
| CA2664799C (en) | 2016-01-05 |
| AU2007305595B2 (en) | 2012-10-04 |
| AU2007305595C1 (en) | 2014-10-02 |
| JP2011201913A (ja) | 2011-10-13 |
| CA2664799A1 (en) | 2008-04-17 |
| EP2075005A4 (en) | 2010-09-01 |
| EP2075005A1 (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009116273A (ru) | Вакцина ipv-dpt | |
| Brown | The history of research in foot-and-mouth disease | |
| Bakker et al. | Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV | |
| TWI477606B (zh) | 用於疫苗生產之高效價小兒麻痺病毒之製造 | |
| Tiwari et al. | Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus | |
| CN101695570B (zh) | 一种手足口病单、双价灭活疫苗及其制备方法 | |
| WO2023045426A1 (zh) | 柯萨奇病毒a16型毒株及其免疫原性组合物和应用 | |
| CN102058882B (zh) | 一种制备甲型肝炎灭活疫苗的方法 | |
| DK3010537T3 (en) | PROCEDURE FOR PREVENTING AGGREGATION OF VIRUS COMPONENTS | |
| CN105396129B (zh) | 一种利用脊髓灰质炎减毒株生产的灭活疫苗 | |
| Li et al. | Removing residual DNA from Vero-cell culture-derived human rabies vaccine by using nuclease | |
| CN1617741A (zh) | 制备纯化的甲型肝炎病毒体和疫苗制剂的方法 | |
| CN100389207C (zh) | 快速、灵敏检测甲肝减毒活疫苗病毒感染性滴度的方法 | |
| CN105624065A (zh) | 一种百日咳杆菌培养基 | |
| CN108055827A (zh) | 高成长肠病毒71型病毒株及其疫苗 | |
| JP5084214B2 (ja) | Ｉｐｖワクチン | |
| Pujar et al. | Modern Production Strategies in the Vaccine Industry | |
| RU2799602C1 (ru) | Штамм А/Иран/2018 вируса ящура Aphtae epizooticae типа А для изготовления биопрепаратов для диагностики и специфической профилактики ящура типа А | |
| CN109602899B (zh) | 一种增强病毒抗原免疫原性的皮内注射技术及其在手足口病疫苗研究中的应用 | |
| Mazurkova et al. | Optimization of Reproduction Conditions of the Vaccine Cold-Adapted Recombinant Strains of Influenza Virus in Roller-Cultivated MDCK Cells | |
| Dogadov et al. | Enteral viral hepatitis in monkeys | |
| Alvim et al. | Production of Zika virus-like particles (VLPs) by perfusion processes | |
| Wieczorek et al. | The detection of enteroviruses in sewage using Caco-2 cells | |
| EA201800511A1 (ru) | Технология получения вакцины против геморрагической лихорадки с почечным синдромом | |
| Cheng et al. | Antigenic mapping of enterovirus A71 from Taiwan and Southeast Asia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20141119 |